🔍 Description:

MOTS-C is a mitochondrial-derived peptide (MDP) that plays a critical role in metabolic regulation, with a significant influence on energy production, insulin sensitivity, and fat metabolism. Discovered relatively recently, MOTS-C is unique among peptides because it is encoded within the mitochondrial DNA, unlike most peptides, which are encoded in nuclear DNA. This peptide has garnered attention for its potential to improve metabolic health, enhance physical performance, and promote longevity by optimizing mitochondrial function, which is essential for cellular energy production and overall vitality.

💪 Health Benefits:

– Metabolic Regulation: MOTS-C enhances insulin sensitivity, thereby improving glucose metabolism. This makes it a promising candidate for reducing the risk of metabolic disorders such as type 2 diabetes. By activating AMPK (adenosine monophosphate-activated protein kinase), a key enzyme in cellular energy homeostasis, MOTS-C helps cells utilize glucose more effectively, thereby reducing blood sugar levels and improving overall metabolic health.

– Fat Loss: MOTS-C promotes fat loss by increasing energy expenditure and enhancing mitochondrial function. It has been shown to stimulate fatty acid oxidation, helping the body to burn fat more efficiently. Additionally, MOTS-C may reduce fat accumulation by inhibiting fat storage pathways, making it a valuable tool for weight management and combating obesity.

– Longevity: The peptide’s potential anti-aging effects are linked to its ability to improve mitochondrial function and protect against metabolic decline associated with aging. MOTS-C has been studied for its role in promoting cellular resilience to stress, reducing inflammation, and potentially extending lifespan. These effects are particularly relevant in the context of age-related diseases, where mitochondrial dysfunction is a common underlying factor.

💉 Dosing/Administration:

– Typical Dosage: Currently, there is no standardized dosage for MOTS-C, as it is primarily used in experimental and clinical research settings. Dosages in studies typically range from 5 mg to 10 mg per week, administered in divided doses. However, the optimal dosage can vary depending on individual health goals, such as improving metabolic health or enhancing athletic performance.

– Administration Method: MOTS-C is usually administered via subcutaneous injection. The peptide is often injected into the abdominal area, as it is readily absorbed into the bloodstream from this site. The frequency and duration of administration depend on the specific metabolic or health goals being targeted.

– Cycling: Usage is often cycled with breaks to maximize benefits and prevent desensitization. A common cycle might involve several weeks of active administration followed by a period of rest to allow the body to reset. This cycling approach helps to sustain the peptide’s efficacy over time, particularly in long-term applications such as metabolic regulation or anti-aging therapies.

⚠️ Side Effects and Safety:

– Common Side Effects: MOTS-C is generally well-tolerated, with minimal side effects reported in the literature. Some individuals may experience mild injection site reactions, such as redness or irritation, but these effects are typically transient.

– Safety Profile: MOTS-C is considered safe for use in metabolic regulation, although it is still under investigation, and its long-term effects are not fully understood. The peptide’s safety profile is promising, but ongoing research is needed to fully elucidate its potential risks and benefits. Individuals interested in using MOTS-C, particularly for extended periods, should do so under the guidance of a healthcare provider to ensure appropriate monitoring and to mitigate any potential risks.

🔬 Research Insights:

– Mitochondrial Function: MOTS-C has been shown to counteract the effects of a high-fat diet and age-related insulin resistance in animal studies, making it a potential therapeutic agent for metabolic diseases. It works by activating pathways that enhance mitochondrial function and energy expenditure, which are crucial for maintaining metabolic health.

– Exercise Performance: Some studies suggest that MOTS-C can enhance physical performance by increasing energy availability and reducing exercise-induced oxidative stress. This makes it an attractive option for athletes and individuals looking to improve their fitness levels.

– Age-Related Diseases: Given its role in improving mitochondrial function, MOTS-C is being explored as a potential treatment for age-related diseases, including cardiovascular diseases and neurodegenerative disorders, where mitochondrial dysfunction plays a key role.

References:

1. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” *Cell Metab.* 2015;21(3):443–54.

2. Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. “MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.” *Int J Mol Sci.* 2022;23(19):11991.

3. Gao Y, Wei X, Wei P, Lu H, Zhong L, Tan J, Liu H, Liu Z. “MOTS-c Functionally Prevents Metabolic Disorders.” *Metabolites.* 2023;13(1):125.

4. Kim, K.H.; Son, J.M.; Benayoun, B.A.; Lee, C. “The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress.” *Cell Metab.* 2018;28:516–524.

5. Lee, C.; Kim, K.H.; Cohen, P. “MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.” *Free Radic. Biol. Med.* 2016;100:182–187.

6. Reynolds, J.C., et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” *Nat. Commun.* 2021;12:1–11.

7. Zarse, K.; Ristow, M. “A mitochondrially encoded hormone ameliorates obesity and insulin resistance.” *Cell Metab.* 2015;21:355–356.

8. Lu H, Wei M, Zhai Y, Li Q, Ye Z, Wang L, Luo W, Chen J, Lu Z. “MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction.” *J Mol Med (Berl).* 2019;97(4):473-485.

9. D’Souza, R.F., et al. “Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition.” *Aging.* 2020;12:5244–5258.

10. Marulanda, J., et al. “Mechanisms of vascular calcification and associated diseases.” *Curr. Pharm. Des.* 2014;20:5801–5810.

11. Wei, M., et al. “Mitochondrial-derived peptide MOTS-c attenuates vascular calcification and secondary myocardial remodeling via adenosine monophosphate-activated protein kinase signaling pathway.” *Cardiorenal. Med.* 2020;10:42–50.

12. Jäger, S., et al. “AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α.” *Proc. Natl. Acad. Sci. USA.* 2007;104:12017–12022.

13. Schnyder, S., et al. “Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise.” *Bone.* 2015;80:115–125.

14. Li, S., et al. “MOTS-c and Exercise Restore Cardiac Function by Activating of NRG1-ErbB Signaling in Diabetic Rats.” *Front Endocrinol.* 2022;13:812032.

15. BioSpace. “CohBar completes phase 1a and initiates phase 1b stage of clinical trial for CB4211 under development for NASH and Obesity.” BioSpace. 2019. [Link](https://www.biospace.com/article/releases/CohBar-Completes-Phase-1a-and-initiates-Phase1b-Stage-of-Clinical-Trial-of-CB4211-Under-Development-for-NASH-and-ObesityMilestone-for-First-Mitochondrial-Based-Therapeutic-in-Humans)

16. Zheng Y, Wei Z, Wang T. “MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.” *Front Endocrinol (Lausanne).* 2023;14:1120533.

17. Wang, S., et al. “Peptides encoded by noncoding genes: challenges and perspectives.” *Sig Transduct Target Ther.* 2019;4:57. [DOI: 10.1038/s41392-019-0092-3](https://doi.org/10.1038/s41392-019-0092-3)

This poster presents results from a clinical trial studying CB4211, an analog of the mitochondrial peptide MOTS-c, for treating nonalcoholic fatty liver disease (NAFLD) in obese subjects. Key points include:

1. Study design: Double-blind, randomized, placebo-controlled trial with 23 high-risk NAFLD subjects.

2. Treatment: Subjects received daily subcutaneous injections of 25 mg CB4211 or placebo for 4 weeks.

3. Key findings:

   – Significant reductions in liver injury biomarkers ALT and AST compared to placebo

   – Reduced fasting glucose levels

   – Trend towards reduced body weight

   – Liver fat content decreased in both CB4211 and placebo groups, possibly due to standardized diet during the study

4. Safety: CB4211 was generally safe and well-tolerated, with mild to moderate injection site reactions being the most common treatment-related adverse event.

5. Mechanism: CB4211 enhances insulin signaling in adipocytes, hepatocytes, and muscle cells.

6. Conclusion: Results support further development of CB4211 as a potential treatment for nonalcoholic steatohepatitis (NASH).

The study suggests that CB4211, as a MOTS-c analog, shows promise in improving markers of liver injury and metabolism in obese NAFLD patients, warranting further investigation.